Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 7, 2010, Pages 3111-3116

  Rai, Deepak ^a   Kim, Sang Woo ^a   McKeller, Morgan R ^a   Dahia, Patricia L M ^a   Aguiar, Ricardo C T ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

B lymphocytes; Bone morphogenetic protein; Lymphoma; miR 155; Transforming growth factor

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; MICRORNA; MICRORNA 155; PROTEIN P21; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; GENE OVEREXPRESSION; GENOME ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR XENOGRAFT;

BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SMAD5 PROTEIN; STATISTICS, NONPARAMETRIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 77649242925     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910667107     Document Type: Article

References (27)

1. Abramson JS, Shipp MA (2005) Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106: 1164-1174.
2. Bartel DP (2009) MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233.
3. Rai D, Karanti S, Jung I, Dahia PL, Aguiar RC (2008) Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet 181:8-15.
4. Eis PS, et al. (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102:3627-3632.
5. Costinean S, et al. (2006) Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103: 7024-7029.
6. O'Connell RM, et al. (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205:585-594.
7. Dorsett Y, et al. (2008) MicroRNA-155 suppresses activation-induced cytidine deaminasemediated Myc-Igh translocation. Immunity 28:630-638.
8. Lu LF, et al. (2009) Foxp3-dependentmicroRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30:80-91.
9. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D (2009) Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 106:7113-7118.
10. Vigorito E, et al. (2007) microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 27:847-859.
11. Massagué J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19: 2783-2810.
12. Goumans MJ, et al. (2003) Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12:817-828.
13. Daly AC, Randall RA, Hill CS (2008) Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28:6889-6902.
14. Liu IM, et al. (2009) TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J 28:88-98.
15. Wrighton KH, Lin X, Yu PB, Feng XH (2009) Transforming growth factor beta can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J Biol Chem 284:9755-9763.
16. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006) Transforming growth factorbeta regulation of immune responses. Annu Rev Immunol 24:99-146.
17. Massagué J, Gomis RR (2006) The logic of TGFbeta signaling. FEBS Lett 580:2811-2820.
18. Chen CR, Kang Y, Siegel PM, Massagué J (2002) E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110:19-32.
19. Ota T, et al. (2002) Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol 193:299-318.
20. Pangas SA, et al. (2008) Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol 28:248-257.
21. McReynolds LJ, Gupta S, Figueroa ME, Mullins MC, Evans T (2007) Smad1 and Smad5 differentially regulate embryonic hematopoiesis. Blood 110:3881-3890.
22. Monti S, et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-1861.
23. Tavazoie SF, et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147-152.
24. Xiao C, et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9:405-414.
25. Thai TH, et al. (2007) Regulation of the germinal center response by microRNA-155. Science 316:604-608.
26. Li C, et al. (2009) Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 113:6681-6690.
27. Smith PG, et al. (2005) The phosphodiesterase PDE4B limits cAMP-associated PI3K/ AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 105:308-316.